Skip to content
TrialScanner

NCT02401815

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

Phase 1/Phase 2CompletedCOGTLead

Registry record

Lead sponsor
Cogent Biosciences, Inc.
Conditions
Gastrointestinal Stromal Tumors
Primary completion
May 11, 2020Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02401815 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02401815: CGT9486 (Formerly Known as... | TrialScanner